Mechanism of autism

Last updated

The mechanisms of autism are the molecular and cellular processes believed to cause or contribute to the symptoms of autism. Multiple processes are hypothesized to explain different autism spectrum features. These hypotheses include defects in synapse structure and function, [1] [2] reduced synaptic plasticity, [3] disrupted neural circuit function, gut–brain axis dyshomeostasis, [4] [5] [6] neuroinflammation, [7] and altered brain structure or connectivity. [8] [9] [10] [11] Autism symptoms stem from maturation-related changes in brain systems. [9] The mechanisms of autism are divided into two main areas: pathophysiology of brain structures and processes, and neuropsychological linkages between brain structures and behaviors, with multiple pathophysiologies linked to various autism behaviors. [10]

Contents

Evidence suggests gut–brain axis abnormalities may contribute to autism. [6] [4] Studies propose that immune, gastrointestinal inflammation, autonomic nervous system dysfunction, gut microbiota alterations, and dietary metabolites may contribute to brain neuroinflammation and dysfunction. [5] Additionally, enteric nervous system abnormalities could play a role in neurological disorders by allowing disease pathways from the gut to impact the brain. [5]

Synaptic dysfunction also appears to be implicated in autism, with some mutations disrupting synaptic pathways involving cell adhesion. [2] Evidence points to teratogens affecting the early developmental stages, suggesting autism arises very early, possibly within the first eight weeks after conception. [12]

Neuroanatomical studies support that autism may involve abnormal neuronal growth and pruning, leading to brain enlargement in some areas and reduction in others. [13] Functional neuroimaging studies show reduced activation in somatosensory cortices during theory of mind tasks in autistic individuals and highlight potential imbalances in neurotransmitters like glutamate and Γ-aminobutyric acid that may underlie autism's behavioral manifestations. [14]

Pathophysiology

The amygdala, cerebellum, and many other brain regions have been implicated in autism. Autismbrain.jpg
The amygdala, cerebellum, and many other brain regions have been implicated in autism.

Unlike some brain disorders which have clear molecular hallmarks that can be observed in every affected individual, such as Alzheimer's disease or Parkinson's disease, autism does not have a unifying mechanism at the molecular, cellular, or systems level. The autism spectrum may comprise a small set of disorders that converge on a few common molecular pathways, or it may be a large set of disorders with diverse mechanisms. [16] Autism appears to result from developmental factors that affect many or all functional brain systems. [17] Some factors may disturb the timing of brain development rather than the final product. [15]

Listed below are some characteristic findings in ASD brains on molecular and cellular levels regardless of the specific genetic variation or mutation contributing to autism in a particular individual:

Brain growth

Neuroanatomical studies and the association between autism and teratogens strongly suggest that autism affects brain development soon after conception. [12] This anomaly appears to start a cascade of pathological events in the brain that are significantly influenced by environmental factors. [20] Just after birth, the brains of children with autism tend to grow faster than usual, followed by normal or relatively slower growth in childhood. [21] It is unknown whether early brain overgrowth occurs in all children with autism. It appears to be most prominent in the frontal and temporal lobes, which are associated with higher cognitive specializations such as social cognition, and language development. [22] Hypotheses for the cellular and molecular bases of pathological early overgrowth include an excess of neurons that causes local overconnectivity in key brain regions, [21] and disturbed neuronal migration during early gestation. [23] [24]

Synapse dysfunction

Synapse and dendritic spine growth may be disrupted in autism due to impaired neurexinneuroligin cell-adhesion signaling [25] or dysregulated synthesis of synaptic proteins. [26] [27] Disrupted synaptic development may also contribute to epilepsy, which may explain why the two conditions are associated. [28] Studies have suggested that excitatory–inhibitory networks may be imbalanced in autism. [24]

Neurotransmitters such as serotonin, dopamine, and glutamate have been implicated in autism. [1] Fragile X, the most common genetic cause of autism, is linked to dysfunction of group I metabotropic glutamate receptors (mGluR), leading some to consider their potential role in autism. [29]

Altered circuit connectivity

Autistic individuals tend to use different brain areas (yellow) for a movement task compared to a control group (blue). Powell2004Fig1A.jpeg
Autistic individuals tend to use different brain areas (yellow) for a movement task compared to a control group (blue).

The underconnectivity theory of autism posits that autistic people tend to have fewer high-level neural connections and less global synchronization, along with an excess of low-level processes. [31] Functional connectivity studies have found both hypo- and hyperconnectivity in brains of autistic people. [32] Hypoconnectivity is commonly observed for interhemispheric (e.g. lower neuron density in corpus callosum) [33] and cortico-cortical functional connectivity. [34] Some studies have found local overconnectivity in the cerebral cortex and weak functional connections between the frontal lobe and the rest of the cortex. [35] Abnormal default mode network (task-negative) connectivity is often observed. Toggling between task-negative network activation and task-positive network activation (consisting of the dorsal attention network and salience network) may be less efficient, possibly reflecting a disturbance of self-referential thought. [36] Such patterns of low function and aberrant activation in the brain may depend on whether the brain is performing social or nonsocial tasks. [37]

Some studies have suggested that autism is a disorder of the association cortex. [38] Event-related potentials with respect to attention, orientation to auditory and visual stimuli, novelty detection, language and face processing, and information storage are altered in autistic individuals; several studies have found a preference for nonsocial stimuli. [39] Magnetoencephalography studies have observed delayed processing of auditory signals in autistic children. [40]

The mirror neuron system (MNS) theory of autism hypothesizes that disrupted development of the MNS impairs autistic people's ability to imitate others, leading to core autistic features of social impairment and communication difficulties. In animals, the MNS activates when an animal performs an action or observes another animal perform the same action. The MNS may contribute to an individual's understanding of other people by enabling the modeling of their behavior via embodied simulation of their actions, intentions, and emotions. [41] [42] Several studies have tested this hypothesis by demonstrating structural abnormalities in MNS regions of individuals with ASD, delay in the activation in the core circuit for imitation in individuals with ASD, and a correlation between reduced MNS activity and severity of the syndrome in children with ASD. [43] However, individuals with autism also have abnormal brain activation in many circuits outside the MNS [44] and the MNS theory does not explain the normal performance of children with autism on imitation tasks that involve a goal or object. [45]

Common copy number variation associations have suggested similarities between the mechanisms of autism and schizophrenia. For loci such as 16p11.2, 16p13.1, 22p11, and 22q13, deletion is associated with autism whereas duplication is associated with schizophrenia. Conversely, 1q21.1 and 22p11.2 duplication is associated with autism and deletion with schizophrenia. [46]

It has been observed that people with ASD tend to have preferential processing of information on the left hemisphere compared to the right. The left hemisphere is associated with processing information related to details whereas the right hemisphere is associated with processing information in a more global and integrated sense that is essential for pattern recognition. For example, visual information like face recognition is normally processed by the right hemisphere which tends to integrate all information from an incoming sensory signal, whereas an ASD brain preferentially processes visual information in the left hemisphere where information tends to be processed for local details of the face rather than the overall configuration of the face. This left lateralization negatively impacts both facial recognition and spatial skills. [33] [47]

Inflammation

The immune system is thought to play an important role in autism. Children with autism have been found by researchers to have inflammation of both the peripheral and central immune systems as indicated by increased levels of pro-inflammatory cytokines and significant activation of microglia. [48] [49] [7] Biomarkers of abnormal immune function have also been associated with increased impairments in behaviors that are characteristic of the core features of autism such as, deficits in social interactions and communication. [49] Interactions between the immune system and the nervous system begin early during the embryonic stage of life, and successful neurodevelopment depends on a balanced immune response. It is thought that activation of a pregnant mother's immune system such as from environmental toxicants or infection can contribute to causing autism through causing a disruption of brain development. [50] [51] [52] This is supported by recent studies that have found that infection during pregnancy is associated with an increased risk of autism. [53] [54]

Some evidence suggests that gut–brain axis abnormalities may be involved by means of impaired serotonin signaling and inflammation. [6] A 2015 review proposed that immune dysregulation, gastrointestinal inflammation, autonomic nervous system malfunction, gut microbiota alterations, and food metabolites may cause brain neuroinflammation and dysfunction. [4] A 2016 review concluded that enteric nervous system abnormalities might play a role in neurological disorders such as autism. [5]

Metabolism

Some data suggests neuronal overgrowth observed in autism may be caused by an increase in several growth hormones [55] or impaired regulation of growth factor receptors. Some inborn errors of metabolism are associated with autism, but probably account for less than 5% of cases. [56]

Brain connectivity

Brains of autistic individuals have been observed to have abnormal connectivity and the degree of these abnormalities directly correlates with the severity of autism. Following are some observed abnormal connectivity patterns in autistic individuals: [33] [18]

Gut-immune-brain axis

46% to 84% of autistic individuals have GI-related problems like reflux, diarrhea, constipation, inflammatory bowel disease, and food allergies. [58] It has been observed that the makeup of gut bacteria in autistic people is different than that of neurotypical individuals which has raised the question of influence of gut bacteria on ASD development via inducing an inflammatory state. [59] Listed below are some research findings on the influence of gut bacteria and abnormal immune responses on brain development: [59]

Social brain interconnectivity

A number of discrete brain regions and networks among regions that are involved in dealing with other people have been discussed together under the rubric of the social brain. As of 2012, there is a consensus that autism spectrum is likely related to problems with interconnectivity among these regions and networks, rather than problems with any specific region or network. [60]

Temporal lobe

Functions of the temporal lobe are related to many of the deficits observed in individuals with ASDs, such as receptive language, social cognition, joint attention, action observation, and empathy. The temporal lobe also contains the superior temporal sulcus and the fusiform face area, which may mediate facial processing. It has been argued that dysfunction in the superior temporal sulcus underlies the social deficits that characterize autism. Compared to neurotypical individuals, one study found that individuals with high-functioning autism had reduced activity in the fusiform face area when viewing pictures of faces. [61] [ verification needed ]

Mitochondria

ASD could be linked to mitochondrial disease, a basic cellular abnormality with the potential to cause disturbances in a wide range of body systems. [62] A 2012 meta-analysis study, as well as other population studies show that approximately 5% of autistic children meet the criteria for classical mitochondrial dysfunction. [63] It is unclear why this mitochondrial disease occurs, considering that only 23% of children with both ASD and mitochondrial disease present with mitochondrial DNA abnormalities. [63]

Serotonin

Serotonin is a major neurotransmitter in the nervous system and contributes to formation of new neurons (neurogenesis), formation of new connections between neurons (synaptogenesis), remodeling of synapses, and survival and migration of neurons, processes that are necessary for a developing brain and some also necessary for learning in the adult brain. 45% of ASD individuals have been found to have increased blood serotonin levels. [18] Abnormalities in the serotonin transporter have also been found in ASD individuals. It has been hypothesized that increased activity of serotonin in the developing brain may facilitate the onset of ASD, with an association found in six out of eight studies between the use of selective serotonin reuptake inhibitors (SSRIs) by the pregnant mother and the development of ASD in the child exposed to SSRI in the antenatal environment. [64]

The study could not definitively conclude SSRIs caused the increased risk for ASD due to the biases found in those studies, and the authors called for more definitive, better conducted studies. [65] Confounding by indication has since then been shown to be likely. [66] However, it is also hypothesized that SSRIs may help reduce symptoms of ASD and even positively affect brain development in some ASD patients. [18]

Reduced NMDA‐receptor function

Reduced NMDA receptor function has been linked to reduced social interactions, locomotor hyperactivity, self-injury, prepulse inhibition (PPI) deficits, and sensory hypersensitivity, among others. Results suggest that NMDA dysregulation could contribute to core ASD symptoms. [67]

Abnormal folate metabolism

Several lines of evidence indicate abnormalities of folate metabolism in ASD. These abnormalities can lead to a decrease in 5-methyltetrahydrofolate production, alter the production of folate metabolites and reduce folate transport across the blood-brain barrier and in neurons. The most significant abnormalities of folate metabolism associated with ASD may be autoantibodies to the alpha folate receptor (FRα). These autoantibodies have been associated with cerebral folate deficiency. Autoantibodies can bind to FRα and greatly impair its function.

In 2013, one study reported that 60% and 44% of 93 children with ASD were positive for FRα-blocking and binding autoantibodies, respectively. This high rate of anti-FRα autoantibody positivity was confirmed by Ramaekers et al. who compared 75 children with ASD to 30 non-autistic "controls". These controls were children who had a developmental delay, but did not have ASD. FRα-blocking autoantibodies were positive in 47% of children with ASD, but only in 3% of children without ASD.

Many children with ASD and cerebral folate deficiency have marked improvements in their clinical status when taking folinic acid.

A series of five children with cerebral folate deficiency and low functioning autism with neurological deficits found a complete reduction of ASD symptoms with the use of folinic acid in a child and substantial improvements in communication in two other children. [68] [69] [70]

Abnormal redox metabolism

An imbalance in glutathione-dependent redox metabolism has been shown to be associated with autism spectrum disorder (ASD).[ citation needed ] Glutathione synthesis and intracellular redox balance are related to folate metabolism and methylation, metabolic pathways that have also been shown to be abnormal in ASD. Together, these metabolic abnormalities define a distinct endophenotype of TSA closely associated with genetic, epigenetic and mitochondrial abnormalities, as well as environmental factors related to ASD. Glutathione is involved in neuroprotection against oxidative stress and neuroinflammation by improving the antioxidant stress system.

In autistic children, studies have shown that glutathione metabolism can be improved:[ citation needed ]

Interestingly, recent DBPC studies have shown that N-acetyl-1-cysteine, a glutathione precursor supplement, is effective in improving the symptoms and behaviors associated with ASD. [71] However, glutathione was not measured in these studies.

Small, medium and large DPBC trials and open small and medium-sized clinical trials demonstrate that new treatments for children with ASD for oxidative stress are associated with improvements in baseline symptoms of ASD, sleep, gastrointestinal symptoms, hyperactivity, seizures and parental impression, sensory and motor symptoms. These new treatments include N-acetyl-l-cysteine, methylcobalamin with and without oral folinic acid, vitamin C, and a vitamin and mineral supplement that includes antioxidants, enzyme Q10, and B vitamins.

Several other treatments that have antioxidant properties, including carnosine, have also been reported to significantly improve ASD behaviors, suggesting that treatment of oxidative stress could be beneficial for children with ASD. Many antioxidants can also help improve mitochondrial function, suggesting that clinical improvements with antioxidants could occur through a reduction in oxidative stress and an improvement in mitochondrial function.

Some of these treatments can have frequent serious side effects (bronchospasm, etc. ...). [68] [72] [73]

Neuropsychology

Two major categories of cognitive theories have been proposed to explain links between autistic brains and behavior.

Social cognition

The first category focuses on deficits in social cognition. Simon Baron-Cohen's empathizing–systemizing theory postulates that autistic individuals can systemize—that is, they can develop internal rules of operation to handle events inside the brain—but are less effective at empathizing by handling events generated by other agents. An extension, the extreme male brain theory, hypothesizes that autism is an extreme case of the male brain, defined psychometrically as individuals in whom systemizing is better than empathizing. [74] These theories are somewhat related to Baron-Cohen's earlier theory of mind approach, which hypothesizes that autistic behavior arises from an inability to ascribe mental states to oneself and others. The theory of mind hypothesis is supported by the atypical responses of children with autism to the Sally–Anne test for reasoning about others' motivations, [74] and the mirror neuron system theory of autism described in Pathophysiology maps well to the hypothesis. [43] However, most studies have found no evidence of impairment in autistic individuals' ability to understand other people's basic intentions or goals; instead, data suggests that impairments are found in understanding more complex social emotions or in considering others' viewpoints. [75]

Nonsocial cognition

The second category focuses on nonsocial or general processing: the executive functions such as working memory, planning, inhibition. In his review, Kenworthy states that "the claim of executive dysfunction as a causal factor in autism is controversial", however, "it is clear that executive dysfunction plays a role in the social and cognitive deficits observed in individuals with autism". [76] Tests of core executive processes such as eye movement tasks indicate improvement from late childhood to adolescence, but performance never reaches typical adult levels. [77] A strength of the theory is predicting stereotyped behavior and narrow interests; [78] two weaknesses are that executive function is hard to measure [76] and that executive function deficits have not been found in young children with autism. [79]

Weak central coherence theory

Weak central coherence theory hypothesizes that a limited ability to see the big picture underlies the central disturbance in autism. One strength of this theory is predicting special talents and peaks in performance in autistic people. [80] A related theory—enhanced perceptual functioning—focuses more on the superiority of locally oriented and perceptual operations in autistic individuals. [81] Yet another, monotropism, posits that autism stems from a different cognitive style, tending to focus attention (or processing resources) intensely, to the exclusion of other stimuli. [82] These theories map well from the underconnectivity theory of autism.

Issues with categories

Neither category is satisfactory on its own; social cognition theories poorly address autism's rigid and repetitive behaviors, while most of the nonsocial theories have difficulty explaining social impairment and communication difficulties. [83] A combined theory based on multiple deficits may prove to be more useful. [84]

References

  1. 1 2 Levy SE, Mandell DS, Schultz RT (November 2009). "Autism". Lancet. 374 (9701): 1627–1638. doi:10.1016/S0140-6736(09)61376-3. PMC   2863325 . PMID   19819542.
  2. 1 2 Betancur C, Sakurai T, Buxbaum JD (July 2009). "The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders". Trends in Neurosciences. 32 (7): 402–412. doi:10.1016/j.tins.2009.04.003. PMC   10354373 . PMID   19541375. S2CID   8644511.
  3. Walsh CA, Morrow EM, Rubenstein JL (October 2008). "Autism and brain development". Cell. 135 (3): 396–400. doi:10.1016/j.cell.2008.10.015. PMC   2701104 . PMID   18984148.
  4. 1 2 3 Wasilewska J, Klukowski M (2015). "Gastrointestinal symptoms and autism spectrum disorder: links and risks - a possible new overlap syndrome". Pediatric Health, Medicine and Therapeutics (Review). 6: 153–166. doi: 10.2147/PHMT.S85717 . PMC   5683266 . PMID   29388597.
  5. 1 2 3 4 Rao M, Gershon MD (September 2016). "The bowel and beyond: the enteric nervous system in neurological disorders". Nature Reviews. Gastroenterology & Hepatology (Review). 13 (9): 517–528. doi:10.1038/nrgastro.2016.107. PMC   5005185 . PMID   27435372.
  6. 1 2 3 Israelyan N, Margolis KG (June 2018). "Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders". Pharmacological Research (Review). 132: 1–6. doi:10.1016/j.phrs.2018.03.020. PMC   6368356 . PMID   29614380.
  7. 1 2 Rossignol DA, Frye RE (2014). "Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism". Frontiers in Physiology. 5: 150. doi: 10.3389/fphys.2014.00150 . PMC   4001006 . PMID   24795645.
  8. Sarovic D (November 2021). "A Unifying Theory for Autism: The Pathogenetic Triad as a Theoretical Framework". Frontiers in Psychiatry (Review). 12: 767075. doi: 10.3389/fpsyt.2021.767075 . PMC   8637925 . PMID   34867553. S2CID   244119594.
  9. 1 2 Penn HE (February 2006). "Neurobiological correlates of autism: a review of recent research". Child Neuropsychology. 12 (1): 57–79. doi:10.1080/09297040500253546. PMID   16484102. S2CID   46119993.
  10. 1 2 London E (October 2007). "The role of the neurobiologist in redefining the diagnosis of autism". Brain Pathology. 17 (4): 408–411. doi:10.1111/j.1750-3639.2007.00103.x. PMC   8095627 . PMID   17919126. S2CID   24860348.
  11. Baird G, Cass H, Slonims V (August 2003). "Diagnosis of autism". BMJ. 327 (7413): 488–493. doi:10.1136/bmj.327.7413.488. PMC   188387 . PMID   12946972.
  12. 1 2 Arndt TL, Stodgell CJ, Rodier PM (2005). "The teratology of autism". International Journal of Developmental Neuroscience. 23 (2–3): 189–199. doi:10.1016/j.ijdevneu.2004.11.001. PMID   15749245. S2CID   17797266.
  13. Koenig K, Tsatsanis KD, Volkmar FR (2001). "Neurobiology and Genetics of Autism: A Developmental Perspective". In Burack JA, Charman T, Yirmiya N, Zelazo PR (eds.). The development of autism: perspectives from theory and research. Mahwah, N.J.: L. Erlbaum. pp. 73–92. ISBN   9780805832457. OCLC   806185029.
  14. Estes ML, McAllister AK (August 2016). "Maternal immune activation: Implications for neuropsychiatric disorders". Science. 353 (6301): 772–777. Bibcode:2016Sci...353..772E. doi:10.1126/science.aag3194. PMC   5650490 . PMID   27540164.
  15. 1 2 Amaral DG, Schumann CM, Nordahl CW (March 2008). "Neuroanatomy of autism". Trends in Neurosciences. 31 (3): 137–145. doi:10.1016/j.tins.2007.12.005. PMID   18258309. S2CID   18648870.
  16. Geschwind DH (October 2008). "Autism: many genes, common pathways?". Cell. 135 (3): 391–395. doi:10.1016/j.cell.2008.10.016. PMC   2756410 . PMID   18984147.
  17. Müller RA (2007). "The study of autism as a distributed disorder". Mental Retardation and Developmental Disabilities Research Reviews. 13 (1): 85–95. doi:10.1002/mrdd.20141. PMC   3315379 . PMID   17326118.
  18. 1 2 3 4 5 6 7 8 9 10 Chen JA, Peñagarikano O, Belgard TG, Swarup V, Geschwind DH (2015). "The emerging picture of autism spectrum disorder: genetics and pathology". Annual Review of Pathology (Review). 10: 111–144. doi: 10.1146/annurev-pathol-012414-040405 . PMID   25621659.
  19. 1 2 De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. (November 2014). "Synaptic, transcriptional and chromatin genes disrupted in autism". Nature. 515 (7526): 209–215. Bibcode:2014Natur.515..209.. doi:10.1038/nature13772. PMC   4402723 . PMID   25363760.
  20. Casanova MF (October 2007). "The neuropathology of autism". Brain Pathology. 17 (4): 422–433. doi: 10.1111/j.1750-3639.2007.00100.x . PMC   8095561 . PMID   17919128. S2CID   6959302.
  21. 1 2 Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, Kennedy DP, et al. (October 2007). "Mapping early brain development in autism". Neuron. 56 (2): 399–413. doi: 10.1016/j.neuron.2007.10.016 . PMID   17964254. S2CID   10662307.
  22. Geschwind DH (2009). "Advances in autism". Annual Review of Medicine. 60: 367–380. doi:10.1146/annurev.med.60.053107.121225. PMC   3645857 . PMID   19630577.
  23. Schmitz C, Rezaie P (February 2008). "The neuropathology of autism: where do we stand?". Neuropathology and Applied Neurobiology. 34 (1): 4–11. doi:10.1111/j.1365-2990.2007.00872.x. PMID   17971078. S2CID   23551620.
  24. 1 2 Persico AM, Bourgeron T (July 2006). "Searching for ways out of the autism maze: genetic, epigenetic and environmental clues". Trends in Neurosciences. 29 (7): 349–358. doi:10.1016/j.tins.2006.05.010. hdl: 11380/1250937 . PMID   16808981. S2CID   26722022.
  25. Südhof TC (October 2008). "Neuroligins and neurexins link synaptic function to cognitive disease". Nature. 455 (7215): 903–911. Bibcode:2008Natur.455..903S. doi:10.1038/nature07456. PMC   2673233 . PMID   18923512.
  26. Kelleher RJ, Bear MF (October 2008). "The autistic neuron: troubled translation?". Cell. 135 (3): 401–406. doi: 10.1016/j.cell.2008.10.017 . PMID   18984149. S2CID   619383.
  27. Bear MF, Dölen G, Osterweil E, Nagarajan N (January 2008). "Fragile X: translation in action". Neuropsychopharmacology. 33 (1): 84–87. doi: 10.1038/sj.npp.1301610 . PMC   4327813 . PMID   17940551.
  28. Tuchman R, Moshé SL, Rapin I (February 2009). "Convulsing toward the pathophysiology of autism". Brain & Development. 31 (2): 95–103. doi:10.1016/j.braindev.2008.09.009. PMC   2734903 . PMID   19006654.
  29. Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, et al. (December 2007). "Correction of fragile X syndrome in mice". Neuron. 56 (6): 955–962. doi:10.1016/j.neuron.2007.12.001. PMC   2199268 . PMID   18093519.
  30. Powell K (August 2004). "Opening a window to the autistic brain". PLOS Biology. 2 (8): E267. doi: 10.1371/journal.pbio.0020267 . PMC   509312 . PMID   15314667.
  31. Just MA, Cherkassky VL, Keller TA, Kana RK, Minshew NJ (April 2007). "Functional and anatomical cortical underconnectivity in autism: evidence from an FMRI study of an executive function task and corpus callosum morphometry". Cerebral Cortex. 17 (4): 951–961. doi:10.1093/cercor/bhl006. PMC   4500121 . PMID   16772313.
  32. Williams DL, Goldstein G, Minshew NJ (August 2006). "Neuropsychologic functioning in children with autism: further evidence for disordered complex information-processing". Child Neuropsychology. 12 (4–5): 279–298. doi:10.1080/09297040600681190. PMC   1803025 . PMID   16911973.
  33. 1 2 3 4 5 6 7 O'Reilly C, Lewis JD, Elsabbagh M (2017). "Is functional brain connectivity atypical in autism? A systematic review of EEG and MEG studies". PLOS ONE (Review). 12 (5): e0175870. Bibcode:2017PLoSO..1275870O. doi: 10.1371/journal.pone.0175870 . PMC   5414938 . PMID   28467487.
  34. Ha S, Sohn IJ, Kim N, Sim HJ, Cheon KA (December 2015). "Characteristics of Brains in Autism Spectrum Disorder: Structure, Function and Connectivity across the Lifespan". Experimental Neurobiology (Review). 24 (4): 273–284. doi:10.5607/en.2015.24.4.273. PMC   4688328 . PMID   26713076.
  35. Murias M, Webb SJ, Greenson J, Dawson G (August 2007). "Resting state cortical connectivity reflected in EEG coherence in individuals with autism". Biological Psychiatry. 62 (3): 270–273. doi:10.1016/j.biopsych.2006.11.012. PMC   2001237 . PMID   17336944.
  36. Broyd SJ, Demanuele C, Debener S, Helps SK, James CJ, Sonuga-Barke EJ (March 2009). "Default-mode brain dysfunction in mental disorders: a systematic review". Neuroscience and Biobehavioral Reviews. 33 (3): 279–296. doi:10.1016/j.neubiorev.2008.09.002. PMID   18824195. S2CID   7175805.
  37. Di Martino A, Ross K, Uddin LQ, Sklar AB, Castellanos FX, Milham MP (January 2009). "Functional brain correlates of social and nonsocial processes in autism spectrum disorders: an activation likelihood estimation meta-analysis". Biological Psychiatry. 65 (1): 63–74. doi:10.1016/j.biopsych.2008.09.022. PMC   2993772 . PMID   18996505.
  38. Minshew NJ, Williams DL (July 2007). "The new neurobiology of autism: cortex, connectivity, and neuronal organization". Archives of Neurology. 64 (7): 945–950. doi:10.1001/archneur.64.7.945. PMC   2597785 . PMID   17620483.
  39. Jeste SS, Nelson CA (March 2009). "Event related potentials in the understanding of autism spectrum disorders: an analytical review". Journal of Autism and Developmental Disorders. 39 (3): 495–510. doi:10.1007/s10803-008-0652-9. PMC   4422389 . PMID   18850262.
  40. Roberts TP, Schmidt GL, Egeth M, Blaskey L, Rey MM, Edgar JC, et al. (May 2008). "Electrophysiological signatures: magnetoencephalographic studies of the neural correlates of language impairment in autism spectrum disorders". International Journal of Psychophysiology. 68 (2): 149–160. doi:10.1016/j.ijpsycho.2008.01.012. PMC   2397446 . PMID   18336941.
  41. Williams JH (April 2008). "Self-other relations in social development and autism: multiple roles for mirror neurons and other brain bases". Autism Research. 1 (2): 73–90. doi:10.1002/aur.15. PMID   19360654. S2CID   15269399.
  42. Dinstein I, Thomas C, Behrmann M, Heeger DJ (January 2008). "A mirror up to nature". Current Biology. 18 (1): R13 –R18. Bibcode:2008CBio...18..R13D. doi:10.1016/j.cub.2007.11.004. PMC   2517574 . PMID   18177704.
  43. 1 2 Iacoboni M, Dapretto M (December 2006). "The mirror neuron system and the consequences of its dysfunction". Nature Reviews. Neuroscience. 7 (12): 942–951. doi:10.1038/nrn2024. PMID   17115076. S2CID   9463011.
  44. Frith U, Frith CD (March 2003). "Development and neurophysiology of mentalizing". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 358 (1431): 459–473. doi:10.1098/rstb.2002.1218. PMC   1693139 . PMID   12689373.
  45. Hamilton AF (January 2008). "Emulation and mimicry for social interaction: a theoretical approach to imitation in autism". Quarterly Journal of Experimental Psychology. 61 (1): 101–115. doi:10.1080/17470210701508798. PMID   18038342. S2CID   14569936.
  46. Crespi B, Stead P, Elliot M (January 2010). "Evolution in health and medicine Sackler colloquium: Comparative genomics of autism and schizophrenia". Proceedings of the National Academy of Sciences of the United States of America. 107 (Suppl 1): 1736–1741. Bibcode:2010PNAS..107.1736C. doi: 10.1073/pnas.0906080106 . PMC   2868282 . PMID   19955444.
  47. "Autism spectrum disorder - Symptoms and causes". Mayo Clinic. Retrieved 2024-01-26.
  48. Hsiao EY (2013). "Immune Dysregulation in Autism Spectrum Disorder". Neurobiology of Autism. International Review of Neurobiology. Vol. 113. pp. 269–302. doi:10.1016/B978-0-12-418700-9.00009-5. ISBN   9780124187009. PMID   24290389.
  49. 1 2 Onore C, Careaga M, Ashwood P (March 2012). "The role of immune dysfunction in the pathophysiology of autism". Brain, Behavior, and Immunity. 26 (3): 383–392. doi:10.1016/j.bbi.2011.08.007. PMC   3418145 . PMID   21906670.
  50. Patterson PH (July 2011). "Maternal infection and immune involvement in autism". Trends in Molecular Medicine. 17 (7): 389–394. doi:10.1016/j.molmed.2011.03.001. PMC   3135697 . PMID   21482187.
  51. Chaste P, Leboyer M (September 2012). "Autism risk factors: genes, environment, and gene-environment interactions". Dialogues in Clinical Neuroscience. 14 (3): 281–292. doi:10.31887/DCNS.2012.14.3/pchaste. PMC   3513682 . PMID   23226953.
  52. Ashwood P, Wills S, Van de Water J (July 2006). "The immune response in autism: a new frontier for autism research". Journal of Leukocyte Biology. 80 (1): 1–15. CiteSeerX   10.1.1.329.777 . doi:10.1189/jlb.1205707. PMID   16698940. S2CID   17531542. Archived from the original on 5 October 2006.
  53. Lee BK, Magnusson C, Gardner RM, Blomström Å, Newschaffer CJ, Burstyn I, et al. (February 2015). "Maternal hospitalization with infection during pregnancy and risk of autism spectrum disorders". Brain, Behavior, and Immunity. 44: 100–105. doi:10.1016/j.bbi.2014.09.001. PMC   4418173 . PMID   25218900.
  54. Atladóttir HO, Thorsen P, Østergaard L, Schendel DE, Lemcke S, Abdallah M, et al. (December 2010). "Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders". Journal of Autism and Developmental Disorders. 40 (12): 1423–1430. doi:10.1007/s10803-010-1006-y. PMID   20414802. S2CID   23471371.
  55. Hughes JR (December 2009). "Update on autism: a review of 1300 reports published in 2008". Epilepsy & Behavior. 16 (4): 569–589. doi:10.1016/j.yebeh.2009.09.023. PMID   19896907. S2CID   8013774.
  56. Manzi B, Loizzo AL, Giana G, Curatolo P (March 2008). "Autism and metabolic diseases". Journal of Child Neurology. 23 (3): 307–314. doi:10.1177/0883073807308698. PMID   18079313. S2CID   30809774.
  57. "Autism spectrum disorder - Symptoms and causes". Mayo Clinic. Retrieved 2024-01-26.
  58. Al-Beltagi M (May 2021). "Autism medical comorbidities". World Journal of Clinical Pediatrics. 10 (3): 15–28. doi: 10.5409/wjcp.v10.i3.15 . PMC   8085719 . PMID   33972922. Gastrointestinal (GI) disorders are significantly more common in children with ASD; they occur in 46% to 84% of them.
  59. 1 2 3 4 5 6 7 8 Azhari A, Azizan F, Esposito G (July 2019). "A systematic review of gut-immune-brain mechanisms in Autism Spectrum Disorder". Developmental Psychobiology. 61 (5): 752–771. doi:10.1002/dev.21803. hdl: 10220/49107 . PMID   30523646. S2CID   54523742.
  60. Kennedy DP, Adolphs R (November 2012). "The social brain in psychiatric and neurological disorders". Trends in Cognitive Sciences. 16 (11): 559–572. doi:10.1016/j.tics.2012.09.006. PMC   3606817 . PMID   23047070.
  61. Schultz RT (2005). "Developmental deficits in social perception in autism: the role of the amygdala and fusiform face area". International Journal of Developmental Neuroscience. 23 (2–3): 125–141. doi:10.1016/j.ijdevneu.2004.12.012. PMID   15749240. S2CID   17078137.
  62. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, et al. (December 2007). "Mitochondrial disease: a practical approach for primary care physicians". Pediatrics. 120 (6): 1326–1333. doi:10.1542/peds.2007-0391. PMID   18055683. S2CID   4939996.
  63. 1 2 Rossignol DA, Frye RE (March 2012). "Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis". Molecular Psychiatry. 17 (3): 290–314. doi:10.1038/mp.2010.136. PMC   3285768 . PMID   21263444.
  64. "Autism". www.who.int. Retrieved 2024-01-26.
  65. Gentile S (August 2015). "Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods?". Journal of Affective Disorders. 182: 132–137. doi:10.1016/j.jad.2015.04.048. PMID   25985383.
  66. Dragioti E, Solmi M, Favaro A, Fusar-Poli P, Dazzan P, Thompson T, et al. (December 2019). "Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review". JAMA Psychiatry. 76 (12): 1241–1255. doi:10.1001/jamapsychiatry.2019.2859. PMC   6777224 . PMID   31577342.
  67. Gandal MJ, Anderson RL, Billingslea EN, Carlson GC, Roberts TP, Siegel SJ (August 2012). "Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia?". Genes, Brain and Behavior. 11 (6): 740–750. doi:10.1111/j.1601-183X.2012.00816.x. PMC   3808979 . PMID   22726567.
  68. 1 2 Frye RE, Rossignol DA (2014). "Treatments for biomedical abnormalities associated with autism spectrum disorder". Frontiers in Pediatrics. 2: 66. doi: 10.3389/fped.2014.00066 . PMC   4073259 . PMID   25019065.
  69. Ghanizadeh A, Akhondzadeh S, Hormozi M, Makarem A, Abotorabi-Zarchi M, Firoozabadi A (2012). "Glutathione-related factors and oxidative stress in autism, a review". Current Medicinal Chemistry. 19 (23): 4000–4005. doi:10.2174/092986712802002572. PMID   22708999.
  70. "NAC Side Effects: Common, Severe, Long Term". Archived from the original on 2019-05-07. Retrieved 2019-05-06.
  71. Lee TM, Lee KM, Lee CY, Lee HC, Tam KW, Loh EW (February 2021). "Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials". The Australian and New Zealand Journal of Psychiatry. 55 (2): 196–206. doi:10.1177/0004867420952540. PMID   32900213. S2CID   221569908.
  72. Ghanizadeh A, Akhondzadeh S, Hormozi M, Makarem A, Abotorabi-Zarchi M, Firoozabadi A (2012). "Glutathione-related factors and oxidative stress in autism, a review". Current Medicinal Chemistry. 19 (23): 4000–4005. doi:10.2174/092986712802002572. PMID   22708999.
  73. "NAC Side Effects: Common, Severe, Long Term". Archived from the original on 2019-05-07. Retrieved 2019-05-06.
  74. 1 2 Baron-Cohen S (March 2009). "Autism: the empathizing-systemizing (E-S) theory". Annals of the New York Academy of Sciences. 1156 (1): 68–80. Bibcode:2009NYASA1156...68B. doi:10.1111/j.1749-6632.2009.04467.x. PMID   19338503. S2CID   1440395.
  75. Hamilton AF (August 2009). "Goals, intentions and mental states: challenges for theories of autism". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 50 (8): 881–892. CiteSeerX   10.1.1.621.6275 . doi:10.1111/j.1469-7610.2009.02098.x. PMID   19508497.
  76. 1 2 Kenworthy L, Yerys BE, Anthony LG, Wallace GL (December 2008). "Understanding executive control in autism spectrum disorders in the lab and in the real world". Neuropsychology Review. 18 (4): 320–338. doi:10.1007/s11065-008-9077-7. PMC   2856078 . PMID   18956239.
  77. O'Hearn K, Asato M, Ordaz S, Luna B (2008). "Neurodevelopment and executive function in autism". Development and Psychopathology. 20 (4): 1103–1132. doi:10.1017/S0954579408000527. PMID   18838033. S2CID   33559397.
  78. Hill EL (January 2004). "Executive dysfunction in autism" (PDF). Trends in Cognitive Sciences. 8 (1): 26–32. doi:10.1016/j.dr.2004.01.001. PMID   14697400.
  79. Sigman M, Spence SJ, Wang AT (2006). "Autism from developmental and neuropsychological perspectives". Annual Review of Clinical Psychology. 2: 327–355. doi:10.1146/annurev.clinpsy.2.022305.095210. PMID   17716073.
  80. Happé F, Frith U (January 2006). "The weak coherence account: detail-focused cognitive style in autism spectrum disorders". Journal of Autism and Developmental Disorders. 36 (1): 5–25. doi:10.1007/s10803-005-0039-0. PMID   16450045. S2CID   14999943.
  81. Mottron L, Dawson M, Soulières I, Hubert B, Burack J (January 2006). "Enhanced perceptual functioning in autism: an update, and eight principles of autistic perception". Journal of Autism and Developmental Disorders. 36 (1): 27–43. doi:10.1007/s10803-005-0040-7. PMID   16453071. S2CID   327253.
  82. Murray D, Lesser M, Lawson W (May 2005). "Attention, monotropism and the diagnostic criteria for autism" (PDF). Autism. 9 (2): 139–156. doi:10.1177/1362361305051398. PMID   15857859. S2CID   6476917. Archived from the original (PDF) on 19 May 2018. Retrieved 18 March 2018.
  83. Happé F, Ronald A, Plomin R (October 2006). "Time to give up on a single explanation for autism". Nature Neuroscience. 9 (10): 1218–1220. doi:10.1038/nn1770. PMID   17001340. S2CID   18697986.
  84. Rajendran G, Mitchell P (2007). "Cognitive theories of autism" (PDF). Dev Rev. 27 (2): 224–60. doi:10.1016/j.dr.2007.02.001. S2CID   34448439.